An observational study in Genetic Neurodevelopmental Disorders, sponsored by University of Sheffield. Recruiting at 1 site in United Kingdom. Open to participants aged 0 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by University of Sheffield · Observational
Hypogonadism is the medical name for a condition in which levels of the hormones which control sexual development are lower than normal. There are dozens of different causes of hypogonadism. Many people with hypogonadism have a change in a gene. There are many genes that give instructions for the hormones important for sexual development. Changes in one of these genes that stops the gene from working, can cause hypogonadism. In some of these medical conditions, there are additional features such as learning problems. In this study we will search databases to find all the genetic conditions that can be associated with hypogonadism. We will ask a number of people with changes in certain genes, identified from our search, to come to our research clinic. We will ask them about their health and examine them for signs of hypogonadism. For some, we will take blood samples to test for hypogonadism. This project will help us understand how common hypogonadism is, in people with these genetic changes, which will help with their treatment.
352 studies on the registry are indexed under Neurodevelopmental Disorders; 141 are open to participants now.
This study's planned enrollment of 50 is below the median of 200 across 133 observational studies indexed under Neurodevelopmental Disorders.
Browse Neurodevelopmental Disorders studies →University of Sheffield is the lead sponsor of 75 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals with pathogenic CNVs or SNVs in a gene causing a neurodevelopmental disorder.
Especially SOX genes to investigate association with hypogonadism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathogenic SNV or CNV in neurodevelopmental disorders gene of interest parent or carer consents to study
Exclusion Criteria:
parent or carer does not consent to study
Measurement of FSH
Blood sample to measure FSH levels. FSH (IU/l) reference range Male, female 0 - 1 month \<22.0 Roche 24.01.2011 Male 1 month - 6 years \<2.8 Roche 24.01.2011 Male 6 - 11 years \<3.8 Roche 24.01.2011 Male 11 - 14 years \<4.6 Roche 24.01.2011 Male 14 years + 1.5 - 12 Roche 24.01.2011 Females 1 month - 14 years 0 - 11 Roche 24.01.2011 Follicular phase 3.5 - 13 Roche 24.01.2011 Mid-cycle 4.7 - 22 Roche 24.01.2011 Luteal phase 1.7 - 7.7 Roc
Time frame: within 1 month of recruitment
Measurement of LH
Blood sample to assay LH levels. LH (IU/l) reference range Males 0 - 1 year \<3.2 Wiedemann Males 1 - 11 years \<1.4 Roche 24.01.2011 Males 11 - 14 years \<7.8 Roche 24.01.2011 Males 14 - 17 years 1.3 - 9.8 Roche 24.01.2011 Males 17 years + 1.7 - 8.6 Roche 24.01.2011 Females 0 - 6 years \<0.5 Roche 24.01.2011 Females 6 - 11 years \<3.1 Roche 24.01.2011 Females 11 - 14 years \<11.9 Roche 24.01.2011 Follicular Phase 2.4 - 13 Roche 24.01.2011 Mid - cycle 14 - 96 Roche 24.01.2011 Luteal phase 1.0 - 11 Roche 24.01.2011 Females 60y + (post-menopausal) 7.7 - 59 Roche 24.01.2011
Time frame: within 1 month of recruitmen
Measurement of testosterone.
Blood assay of testosterone levels in males. Testosterone (nmol/l) Reference range Males, 6 months - 6 years \<1.12 Roche 24.01.2011 Males 6 - 13 years \<2.37 Roche 24.01.2011 Males 13 - 18 years 0.98 - 38.5 Roche 24.01.2011 Males 18 - 50 years 8.6 - 29 Roche 24.01.2011 Males 50 years + 6.7 - 25.7 Roche 24.01.2011 Females 0 - 1 month 0.7 - 2.2 Soldin 24.01.2011 Females 1 month - 10 years \<0.4 Soldin 24.01.2011 Females 10 - 12 years \<0.9 Soldin 24.01.2011 Females 12 years + 0.3 - 1.7 Roche 24.01.2011 Females 50 years + 0.1 - 1.4 Roche 24.01.2011
Time frame: within 1 month of recruitment.
Physical examination for pubertal staging.
Tanner staging standard exam (testicular volume, body hair development, breast development).
Time frame: within 1- month of recruitment.
General medical examination.
Height \& weight, dysmorphology exam. Full respiratory, cardiac and neurological exam.
Time frame: within 1 month of recruitment
Bone age from x-ray.
X-ray assessment of bone age retrieved from medical notes (optional, only if done in routine clinical care previously).
Time frame: within 1-month of recruitment.
Brain MRI
Result retrieved from medical records, optional only if done as part of routine care.
Time frame: within 1 month of recruitment
Gonadal ultrasound
gonadal ultrasound, optional, if done by usual care team
Time frame: within 1-month of recruitment
Serum oestradiol
Oestradiol (pmol/l) reference range Males 1 - 10 years 18.4 - 73.4 Roche 24.01.2011 Males aged 10 years + 41.4 - 159 Roche 07/09/2017 Females aged 1 - 10 years 22 - 99.1 Roche 24.01.2011 Follicular phase \<91.8 - 854 Roche 02/08/2016 Ovulation phase 151 - 1461 Roche 02/08/2016 Luteal phase \<91.8 - 1251 Roche 02/08/2016 Females post-menopausal \<386 STH study 02/08/2016
Time frame: within 1 month of recruitment
Serum AMH
AntiMullerian Hormone (pmol/l) 2.5th, 5th , Median, 95th , 97.5th 20 - 24 yr 8.7, 10.9, 28.6, 71.0, 83.6 Roche 01/06/2018 25 - 29 yr 6.4, 8.6, 23.6, 64.6, 70.3 Roche 01/06/2018 30 - 34 yr 4.1, 5.1, 20.0, 54.2, 58.0 Roche 01/06/2018 35 - 39 yr 1.1, 2.9, 14.2, 49.7, 53.5 Roche 01/06/2018 40 - 44 yr 0.419, 0.4, 6.3, 31.7, 39.1 Roche 01/06/2018 45 - 50 yr 0.07, 0.07, 1.39, 12.8, 19.3 Roche 01/06/2018
Time frame: within 1 month of recruitment
Serum thyroid function tests
Free T3 (pmol/l) reference ranges Males, females 0 - 6 days 2.7 - 9.7 Roche 24.01.2011 Males, females 6 days - 3 months 3.0 - 9.3 Roche 24.01.2011 Males, females 3 - 12 months 3.3 - 9.0 Roche 24.01.2011 Males, females 1 - 6 years 3.7 - 8.5 Roche 24.01.2011 Males, females 6 - 11 years 3.9 - 8.0 Roche 24.01.2011 Males, females 11 - 20 years 3.9 - 7.7 Roche 24.01.2011 Males, females 20 years + 3.1 - 6.8 Roche 24.01.2011 Pregnancy, first trimester 3.8 - 6.0 Roche 24.01.2011 Pregnancy, second trimester 3.2 - 5.5 Roche 24.01.2011 Pregnancy, third trimester 3.1 - 5.0 Roche 24.01.2011 Free T4 (pmol/l) Males, females 0 - 6 days 11.0 - 32.0 Roche 24.01.2011 Males, females 6 days - 3 months 11.5 - 28.3 Roche 24.01.2011 Males, females 3 - 12 months 11.9 - 25.6 Roche 24.01.2011 Males, females 1 year + 11.9 - 21.6 Roche 14.03.2023 Pregnancy, first trimester 12.1 - 19.6 Roche 24.01.2011 Pregnancy, second trimester 9.6 - 17 Roche 24.01.2011 Pregnancy, third trimester 8.4 - 15.6 Roche 24.01.2011
Time frame: within 1 month of recruitment
Serum IGF1 level
GF-1 (µg/l) Males, 0 - 3 months No range (comment) 06.10.2020 Males, 3 - 6 months 12 - 94 Roche 06.10.2020 Males, 6 - 12 months 12 - 95 Roche 06.10.2020 Males, 1 year 12 - 96 Roche 06.10.2020 Males, 2 years 14 - 104 Roche 06.10.2020 Males, 3 years 19 - 116 Roche 06.10.2020 Males, 4 years 27 - 134 Roche 06.10.2020 Males, 5 years 37 - 156 Roche 06.10.2020 Males, 6 years 47 - 184 Roche 06.10.2020 Males, 7 years 58 - 216 Roche 06.10.2020 Males, 8 years 68 - 254 Roche 06.10.2020 Males, 9 years 77 - 296 Roche 06.10.2020 Males, 10 years 86 - 343 Roche 06.10.2020 Males, 11 years 94 - 392 Roche 06.10.2020 Males, 12 years 101 - 434 Roche 06.10.2020 Males, 13 years 108 - 467 Roche 06.10.2020 Males, 14 years 115 - 489 Roche 06.10.2020 Males, 15 years 120 - 501 Roche 06.10.2020 Males, 16 years 125 - 503 Roche 06.10.2020 Males, 17 years 129 - 495 Roche 06.10.2020 Males, 18 years 132 - 476 Roche 06.10.2020 Males, 19 years 134 - 450 Roche 06.10.2020 Males, 20 years 136 - 421 Roche 06.10.2020 Males, 2
Time frame: within 1 month recruitment
Serum prolactin
Males, females 0 - 1 year No range (comment) Males 1 year + 86 - 324 Roche 24.01.2011 Females 1 year + 102 - 496 Roche 24.01.2011
Time frame: within 1-month recruitment
serum cortisol
Cortisol (nmol/l) Neonates 50 - 300 Sippell et al 01.06.2012 Adults 6 - 10 am 4 - 8 pm Random or 8.30-9.30 am: Adrenal insufficiency unlikely (NB does not apply to sick patients with high index of suspicion) Synacthen test (30 min cort): Primary adrenal insufficiency unlikely 133 - 537 68 - 327 \>/=350 \>430 Wythenshawe In-house In-house 18.04.2016 21/12/2018 21/12/2018
Time frame: within 1 month recruitment
serum ACTH
ACTH, 7 am - 10 am (ng/l) 7.2 - 63.3 Roche 22/10/2018
Time frame: within 1-month
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for May 2029, 51 months after the start.
Of 67 non-industry observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's planned 51 months is below that.
Counting every sponsor, half of 70 studies reached it within 59 months; a quarter within 32 and three quarters within 101.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →
University of Sheffield